First Results from the ADRRAD Trial – Combination Androgen Deprivation Therapy (ADT), Whole Pelvis Radiotherapy (WPRT) and Radium 223 in Recently Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPCa)

Turner, Philip G.; Jain, Suneil; Mitchell, D.; Hounsell, Alan R.; Biggart, Sandra

doi:10.1016/j.clon.2017.12.014

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of 10 patients on the ADRRAD trial were just presented in abstract form in 2018. 3 So far, the trial shows limited grade 3 adverse events: 4.2%. Seven of the 10 patients had partial response on whole-body magnetic resonance imaging.…”

Section: Resultsmentioning

confidence: 98%

“…This is an ongoing trial analyzing the use of radium-223 in patients who receive definitive prostate radiation EBRT instead of radical prostatectomy for their prostate primary. 3 In this trial, radium-223 is given concurrently with whole pelvis radiation (74Gy to the prostate and 60Gy to the pelvic lymph nodes). Thirty patients are planned for accrual, 20 patients have been accrued thus far.…”

Section: Resultsmentioning

confidence: 99%

“…7 Radium-223 received Food and Drug Administration (FDA) approval in 2013 for mCRPC. 3 Radium-223 targets lesions with bone turnover, thus making it very useful for treating metastatic bone lesions in prostate, and due to its inherent alpha decay properties, there is less normal tissue affected by radium-223 versus its older counterparts, samarium and strontium. 8 A pivotal trial, the ALSYMPCA trial, documented the benefit of radium-223 in metastatic prostate cancer, that is, in mCRPC.…”

Section: Radium-223 and Mcspc Timelinementioning

confidence: 99%

“…O ver the past 5 years, there has been progress in development of novel drugs for metastatic prostate cancer and there are several new drugs that can be used in the frontline setting. [1][2][3] Most of the breakthroughs have been in systemic treatments still targeting the hormone-sensitive nature of prostate cancer (metastatic castrate-sensitive prostate cancer [mCSPC]). Metastatic prostate cancer patients are divided into two groups: mCSPC and metastatic castrationresistant prostate cancer (mCRPC).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer

Dandapani

Wong

Twardowski

2020

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Background: Radium-223 is approved for treatment of bone metastases in metastatic castration-resistant prostate cancer (mCRPC). After the ALSYMPCA trial showed overall survival benefit with the addition of radium-223 to standard of care in mCRPC in 2013, there have been numerous publications and trials using radium-223 in mCRPC. Recently, there has been interest in using radium-223 earlier in the metastatic prostate cancer timeline, in metastatic castrate-sensitive prostate cancer (mCSPC); however, currently, radium-223 in mCSPC treatment is investigational. Aim: A literature search was conducted to review the use of radium-223 in mCSPC treatment from 1980 to 2019. A review of both radium-223 articles and abstracts was performed. Search terms included metastatic prostate cancer and radium-223, mCSPC, hormone-sensitive metastatic prostate cancer, radium-223, and oligometastatic disease. The results were limited to studies involving multiple patients with mCSPC. Conclusion: There are a limited number of studies of radium-223 in mCSPC treatment and the authors report on these studies (two published studies and four ongoing trials). Trials are currently underway to assess if radium-223 could be used in mCSPC as a treatment for bone metastases and micrometastases. Future data from these trials will be informative as to the benefit of radium-223 in mCSPC treatment and may change treatment paradigms for mCSPC. This review will focus on trials assessing the role of radium-223 in mCSPC.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Radium-223 and Mcspc Timelinementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer

Dandapani

Wong

Twardowski

2020

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…This trial highlighted the need for timing of the combined therapy, which was taken on board in the design of the ADRRAD trial (Belfast) where Docetaxel is given prior to the 223 Ra cycles. 7 At the time of writing, no unexpected or dose limiting toxicities have been observed in the 29/30patients recruited. He concluded that a new era for bone targeting with MRTs has commenced, but that many questions regarding the value and safety of combination therapies, initiation of therapy in the CRPC disease course, the response assessment either using whole body MRI or PSMA PET detection and interaction between 223 Ra and the bone microenvironment, remain unanswered.…”

Section: Presentationsmentioning

confidence: 96%

Clinical trials in molecular radiotherapy—Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018

Falzone

Gregory

Aldridge

et al. 2019

The British Journal of Radiology

View full text Add to dashboard Cite

It has been almost a decade since the commentary Molecular radiotherapy — the radionuclide raffle? by Gaze and Flux (2010). The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationally, of championing molecular targeted radionuclide therapy in all its aspects. Here, we report on the recent NCRI–CTRad (Clinical Trials in Molecular Radiotherapy–Tribulations and Triumphs) meeting, held in London on the 8 June 2018. The meeting was organized by the NCRI–CTRad to review the challenges and opportunities for clinical trials in molecular radiotherapy, particularly focussing on investigator-led trials that incorporate imaging and dosimetry, and to discuss how the community can move forward. This meeting was organised in conjunction with the British Nuclear Medicine Society and reflects the progress of Nuclear Medicine in the UK.

show abstract

First Results from the ADRRAD Trial – Combination Androgen Deprivation Therapy (ADT), Whole Pelvis Radiotherapy (WPRT) and Radium 223 in Recently Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPCa)

Cited by 2 publications

References 0 publications

Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer

Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer

Clinical trials in molecular radiotherapy—Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018

Contact Info

Product

Resources

About